Elobixibat

Summary

Elobixibat (CHEMBL3039515) is a phase-3 clinical-stage small molecule (ATC A06AX09) targeting SLC10A2; indicated across 3 conditions including constipation disorder and metabolic dysfunction-associated steatohepatitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A06AX09
• Targets: 1 (SLC10A2)
• Indications: 3 conditions
• Clinical trials: 11
• Chemistry: 695.9 Da · C36H45N3O7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039515
Name	Elobixibat
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9939892
ATC	A06AX09
Molecular formula	C36H45N3O7S2
Molecular weight	695.9
InChIKey	XFLQIRAKKLNXRQ-UUWRZZSWSA-N

SMILES: CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)C1)OCC(=O)N[C@H](C3=CC=CC=C3)C(=O)NCC(=O)O)SC)C4=CC=CC=C4)CCCC

IUPAC name: 2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid

Also known as: A-3309, A3309, AZD-7806, AZD7806, Elobixibat, ELOBIXIBAT

Patent coverage: 242 distinct patent families (780 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 779 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC10A2	Sodium/bile acid and sulphated solute cotransporter 2	Inhibition	8.92	0%	Q12908

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Bile acid receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1H4	8.92	IC50	1.2	nM	CHEMBL_ACT_26686529

Target pathways

Aggregated over 1 target gene(s): SLC10A2.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Recycling of bile acids and salts	1	SLC10A2

Dominant GO biological processes

GO term	Targets
response to bacterium	1
bile acid and bile salt transport	1
monoatomic ion transport	1
sodium ion transport	1
lipid transport	1
transmembrane transport	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	3	MONDO:0002203	HP:0002019
metabolic dysfunction-associated steatohepatitis	2	MONDO:0007027	EFO:1001249

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	5
PHASE4	3
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04784780	PHASE4	UNKNOWN	Long-term Elobixibat for Chronic Constipation
NCT05165199	PHASE4	UNKNOWN	Elobixibat for Chronic Constipation Without Defecation Desire
NCT05703464	PHASE4	TERMINATED	Elobixibat for Chronic Constipation Without Defecation Desire
NCT01827592	PHASE3	TERMINATED	26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
NCT01833065	PHASE3	TERMINATED	Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
NCT01895543	PHASE3	COMPLETED	Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
NCT01007123	PHASE2	COMPLETED	Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation
NCT01038687	PHASE2	COMPLETED	Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
NCT01069783	PHASE2	COMPLETED	Study of A3309 in Patients With Dyslipidemia
NCT02392546	PHASE2	WITHDRAWN	Elobixibat Colonic Motor Function Study
NCT04006145	PHASE2	COMPLETED	A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

9 molecules share ≥1 primary target. Top 9 by shared-target count:

Molecule	Source	Status	Shared targets
CHENODIOL	ChEMBL + PubChem	Phase 4 (approved)	SLC10A2
CYCLOSPORINE	ChEMBL + PubChem	Phase 4 (approved)	SLC10A2
DEOXYCHOLIC ACID	ChEMBL + PubChem	Phase 4 (approved)	SLC10A2
MARALIXIBAT	ChEMBL + PubChem	Phase 4 (approved)	SLC10A2
MARALIXIBAT CHLORIDE	ChEMBL + PubChem	Phase 4 (approved)	SLC10A2
URSODIOL	ChEMBL + PubChem	Phase 4 (approved)	SLC10A2
TAURURSODIOL	ChEMBL	Phase 4 (approved)	SLC10A2
LINERIXIBAT	ChEMBL	Phase 3	SLC10A2
TAURODEOXYCHOLIC ACID	ChEMBL	Phase 2	SLC10A2